A phase 3 trial evaluating Moderna’s investigational seasonal influenza vaccine, mRNA-1010, found the messenger RNA ...
LUCENT-3 trial open-label extension data show 63.5% of adults with ulcerative colitis administered mirikizumab (Omvoh) who ...
Guselkumab (Tremfya) showed higher 24-week fistula remission than placebo in adults with perianal fistulizing Crohn disease.
On the heels of FDA’s clearance, the company plans to begin a Phase Ib/IIa trial evaluating CK0802 in patients who have ...
Lastly, a broader view of clinical outcomes and operational insights is a cornerstone to product value translation. Gathering ...
Execution instability often originates in strategy timing rather than study conduct, which sponsors can correct by ...
In a recent video interview with Applied Clinical Trials, Hal Green, senior solution architect and life sciences vertical ...
In this video interview, Hal Green, senior solution architect and life sciences vertical lead EMEA at Loftware, discusses why ...
Week-24 TRuE-AD4 outcomes with ruxolitinib 1.5% cream showed 84.3% EASI75 and 70.6% IGA Treatment Success among completers continuing PRN after Week-8 response. Enrolled adults had moderate AD ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results